Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
  • Company Profiles
  • Target Profiles
  • Product Profiles
Explore BCIQ profiles by entering a company name.

Nanodimension

BioCentury | Apr 23, 2022
Emerging Company Profile

Octant: leveraging cell barcoding for small molecule design 

Bay Area biotech unveils $80M B round, BMS deal while adding Rick Artis as CSO, Feng Zhang to SAB
BioCentury | May 4, 2021
Emerging Company Profile

Cytoki’s IL-22 program wins support from European syndicate in $45M series A, moves toward clinic for IBD

Emerging Company Profile: Ex-Novo employee leads spinout seeded by Lundbeckfonden
BioCentury | Dec 13, 2019
Finance

NanoDimension backs sight-restoring therapy developer Arctos in series A

For its first life sciences company creation deal in Europe, NanoDimension launches ophthalmic play from third fund
BioCentury | Oct 4, 2019
Company News

Icosavax’s self-assembling vaccine platform

With $51M in series A funds, Icosavax aims to show its de novo protein VLPs make potent vaccines for RSV
BioCentury | May 28, 2019
Finance

NanoDimension adding European focus for new $335M fund

With third fund, NanoDimension planning its first-ever European investments while doubling down on therapeutics
Items per page:
1 - 10 of 68